Precision Biosciences (DTIL) Revenue (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Revenue data on file, last reported at $10.8 million in Q1 2026.

• On a quarterly basis, Revenue rose 37272.41% year-over-year to $10.8 million in Q1 2026; TTM through Mar 2026 was $45.1 million, a 11.87% decrease from a year earlier, with the FY2025 full-year figure at $34.3 million, down 50.12% from the prior year.
• Revenue for Q1 2026 stood at $10.8 million, down from $34.2 million in the prior quarter.
• Over the last five years, Revenue for DTIL reached as high as $49.9 million in Q2 2024 and fell as low as $13000.0 in Q3 2025.
• Historically, Revenue has averaged $11.0 million across 5 years, with a median of $7.4 million in 2022.
• Across the five-year window, Revenue tumbled 99.96% in 2025 and surged 37272.41% in 2026, its largest moves.
• Year by year, Revenue stood at $10.6 million in 2022, then tumbled by 33.59% to $7.0 million in 2023, then slumped by 90.93% to $638000.0 in 2024, then soared by 5261.13% to $34.2 million in 2025, then plunged by 68.31% to $10.8 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $10.8 million in Q1 2026, $34.2 million in Q4 2025, and $13000.0 in Q3 2025.